Lars G. Ekman, M.D., Ph.D.

Dr. Ekman is an executive partner at Sofinnova Ventures, Inc., a position he has held since 2008. He also serves as a director of Ultragenyx Pharmaceutical Inc. He also served as a director and then chair of the board of Amarin Corporation plc (from 2008 to 2022), as a director of Intermune Inc. (from 2006 to 2013), as a director of Ocera Therapeutics, Inc. (from 2009 to 2015), as a director of Spark Therapeutics, Inc. (from 2014 to 2019), and as chair of the board of Sophiris Bio Inc. (from 2010 to 2020). Dr. Ekman co-founded Cebix Incorporated, where he served as Chief Executive Officer from 2009 to 2012. He was President of Research & Development at Elan Corporation, plc (from 2001 to 2007), where he also served as a director (from 2005 to 2012). From 1997 to 2001, Dr. Ekman was Executive Vice President, Research & Development at Schwarz Pharma AG. Prior to that, he held various senior positions at Pharmacia Corporation. Dr. Ekman is a board-certified surgeon with a PhD in experimental biology, and has held several clinical and academic positions in both the United States and Europe. He earned his PhD and MD from the University of Gothenburg, Sweden. Dr. Ekman has served as Chairman of our Board since 2012.